Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Hydroxyzine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 4/20 | 0.98 |
| ▸ | DRD3 | P35462 | 5/20 | 0.98 |
| ▸ | USP2 | O75604 | 3/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.98 |
| ▸ | DRD2 | P14416 | 3/20 | 0.98 |
| ▸ | HRH2 | P25021 | 2/20 | 0.98 |
| ▸ | HTR2A | P28223 | 2/20 | 0.98 |
| ▸ | HTR2B | P41595 | 2/20 | 0.98 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.98 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.98 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.98 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.98 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.98 |
| ▸ | DRD4 | P21917 | 1/20 | 0.98 |
| ▸ | HTR7 | P34969 | 1/20 | 0.98 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.98 |
| ▸ | HTR5A | P47898 | 1/20 | 0.98 |
| ▸ | HTR6 | P50406 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydroxyzine SCHEMBL41448 | 1.00 | DRD3 (0.98) | DRD3HRH1USP2KCNH2CYP2D6 | |
| Hydroxyzine SCHEMBL41450 | 1.00 | DRD3 (0.98) | DRD3HRH1USP2KCNH2CYP2D6 | |
| Hydroxyzine SCHEMBL4492 | 0.99 | DRD3 (1.00) | DRD3HRH1USP2KCNH2CYP2D6 | |
| Hydroxyzine SCHEMBL383277 | 0.99 | DRD3 (1.00) | DRD3HRH1USP2KCNH2CYP2D6 | |
| Hydroxyzine SCHEMBL3061159 | 0.99 | DRD3 (1.00) | DRD3HRH1USP2KCNH2CYP2D6 | |
| Hydroxyzine SCHEMBL4491 | 0.99 | DRD3 (1.00) | DRD3HRH1USP2KCNH2CYP2D6 | |
| Etodroxizine SCHEMBL9064076 | 0.98 | DRD3 (0.98) | DRD3HRH1USP2KCNH2CYP2D6 | |
| Etodroxizine SCHEMBL668191 | 0.98 | DRD3 (0.98) | DRD3HRH1USP2KCNH2CYP2D6 | |
| Hydroxyzine SCHEMBL28290521 | 0.98 | DRD3 (0.98) | DRD3HRH1USP2KCNH2CYP2D6 | |
| Hydroxyzine SCHEMBL15532242 | 0.96 | DRD3 (0.95) | DRD3HRH1USP2KCNH2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 220 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240295545-A1 | GLIOMA THERAPY | IMPERIAL COLLEGE INNOVATIONS LTD (GB) | 2024-09-05 | — | — | US | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| EP-4291900-A1 | GLIOMA THERAPY | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2023-12-20 | — | — | EP | claimed |
| US-20230248734-A1 | ANTIVIRAL COMPOSITION OBTAINED THROUGH DRUG REPOSITIONING | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2023-08-10 | — | — | US | claimed |
| WO-2022172024-A1 | GLIOMA THERAPY | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2022-08-18 | — | — | WO | claimed |
| EP-3918056-A1 | METHOD OF USING HUMAN SPHEROIDS FOR DRUG DISCOVERY | Stemonix Inc. (US) | 2021-12-08 | — | — | EP | claimed |
| US-20200400651-A1 | METHOD OF USING HUMAN SPHEROIDS FOR DRUG DISCOVERY | AXOSIM, INC. | 2020-12-24 | — | — | US | claimed |
| WO-2020160470-A1 | METHOD OF USING HUMAN SPHEROIDS FOR DRUG DISCOVERY | StemoniX Inc. (US) | 2020-08-06 | — | — | WO | claimed |
| EP-3513782-A1 | GEL FORMULATIONS FOR ORAL ADMINISTRATION OF DRUGS, IN PARTICULAR TO DYSPHAGIC PATIENTS | Universita' Degli Studi Di Camerino (IT) | 2019-07-24 | — | — | EP | claimed |
| US-9757376-B2 | Pharmaceutical compositions | GM PHARMACEUTICALS, INC. (US) | 2017-09-12 | — | — | US | claimed |
| CN-103351361-B | The preparation method of LEVO CITRAZINE and dihydrochloride thereof | HUASHUO TECHNOLOGY CO., LTD. (CN) | 2015-07-29 | — | — | CN | claimed |
| US-20140256043-A1 | SMALL CHEMICAL COMPOUND WHICH PROMOTES INDUCTION OF DIFFERENTIATION OF STEM CELLS INTO INSULIN-PRODUCING CELLS AND METHOD FOR INDUCING DIFFERENTIATION OF STEM CELLS INTO INSULIN-PRODUCING CELLS USING SAID SMALL CHEMICAL COMPOUND | KYOTO UNIVERSITY (JP) | 2014-09-11 | — | — | US | claimed |
| CN-103351361-A | Levocetirizine preparation method and levocetirizine dihydrochloride preparation method | HAISO TECHNOLOGY CO LTD | 2013-10-16 | — | — | CN | claimed |
| EP-1641446-A1 | PHARMACEUTICAL COMPOSITIONS INCLUDING AN ANTIHISTAMINE AND A STIMULANT AND USE THEREOF | Pediamed Pharmaceuticals, Inc. (US) | 2006-04-05 | — | — | EP | claimed |
| WO-2004112771-A1 | PHARMACEUTICAL COMPOSITIONS INCLUDING AN ANTIHISTAMINE AND A STIMULANT AND USE THEREOF | PEDIAMED PHARMACEUTICALS, INC. (US) | 2004-12-29 | — | — | WO | claimed |
| US-20040259809-A1 | Pharmaceutical compositions including an antihistamine and a stimulant and method of use thereof | PEDIAMED PHARMACEUTICALS, INC. | 2004-12-23 | — | — | US | claimed |
| US-20030212078-A1 | Topical administration of pharmacological compositions for non-systemic treatment of pruritus | KLEIN GERALD L (US) | 2003-11-13 | — | — | US | claimed |
| WO-2001087236-A2 | TOPICAL ADMINISTRATION OF PHARMACOLOGICAL COMPOSITIONS FOR NON-SYSTEMIC TREATMENT OF PRURITUS | KLEIN GERALD L (US) | 2001-11-22 | — | — | WO | claimed |
| US-20260114475-A1 | ANIMAL FOOD COMPOSITIONS WITH IMPROVED PALATABILITY AND CUSTOMIZABILITY, AND METHODS FOR PREPARING THE SAME | MARS, INCORPORATED (US) | 2026-04-30 | — | — | US | disclosed |
| US-4599359-A | POTENTIATION | Cooper, Stephen A. (US) | 1986-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260114475-A1 | ANIMAL FOOD COMPOSITIONS WITH IMPROVED PALATABILITY AND CUSTOMIZABILITY, AND METHODS FOR PREPARING THE SAME | PIGS, TAS2R13, CEL | HRH1 3408/4885DRD3 1050/4885USP2 3027/4885 |
| US-20230248734-A1 | ANTIVIRAL COMPOSITION OBTAINED THROUGH DRUG REPOSITIONING | SARS1, EIF2AK2, ACE2 | HRH1 3866/4885DRD3 4466/4885USP2 472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.